Vera Therapeutics (VERA) Other Non-Current Assets (2021 - 2026)
Vera Therapeutics' (VERA) quarterly Other Non-Current Assets came in at $1.2 million in Q1 2026, up 917.54% YoY from $114000.0 in Q1 2025, and down 80.17% on a QoQ basis from $5.8 million in Q4 2025.
Vera Therapeutics (VERA) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 6 years of Other Non-Current Assets data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 917.54% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 917.54% YoY) and the FY2025 annual result came in at $5.8 million, up 4365.65% from the prior year.
- Other Non-Current Assets retreated to $1.2 million in Q1 2026, from $5.8 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.8 million in Q4 2025 to a low of $67000.0 in Q1 2022.
- A 5-year average of $1.0 million and a median of $460000.0 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 77.13% — and 2025, when it surged 4365.65%.
- Tracing VERA's Other Non-Current Assets over 5 years: stood at $293000.0 in 2022, then surged by 64.51% to $482000.0 in 2023, then plunged by 72.82% to $131000.0 in 2024, then surged by 4365.65% to $5.8 million in 2025, then tumbled by 80.17% to $1.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.2 million (Q1 2026), $5.8 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | 5.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.49 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 5.85 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.55 Mn |
| Mar 31, 2025 | 114,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Jun 30, 2024 | 460,000.00 |
| Mar 31, 2024 | 473,000.00 |
| Dec 31, 2023 | 482,000.00 |
| Sep 30, 2023 | 470,000.00 |
| Jun 30, 2023 | 465,000.00 |
| Mar 31, 2023 | 293,000.00 |
| Dec 31, 2022 | 293,000.00 |
| Sep 30, 2022 | 149,000.00 |
| Jun 30, 2022 | 82,000.00 |
| Mar 31, 2022 | 67,000.00 |
| Dec 31, 2021 | 51,000.00 |
| Sep 30, 2021 | 293,000.00 |